January 18, 2023

As Global Sponsor, CooperVision’s Support Expands Language Options and
Extends Access to New Markets

SAN RAMON, CALIF., January 18, 2023—CooperVision, a global leader in myopia management and control, has announced its sponsorship of Ocumetra’s mEYE™ Guide, a parent conversation tool for eye care professionals (ECPs), and mEYE™ Gauge, an axial length estimator. This partnership will broaden access to the tools with additional languages, extending their capabilities to non-English speaking markets worldwide.

Despite rising global prevalence and severity of myopia, ECPs around the world recognize that parents often don't understand the need for myopia management and find that it can take a lot of time to thoroughly explain the concept and treatment options.1

“CooperVision is dedicated to broadening access to tools and resources that empower eye care professionals to combat childhood myopia and help ensure the disease ​is treated with urgency,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision. “Our partnership with Ocumetra complements our investment in evidence-based myopia control interventions, including MiSight® 1 day – the first and only soft contact lens approved* by the U.S. FDA and China NMPA to slow the progression of myopia in age-appropriate children.2†

Through intuitive, visual information such as refraction centile charts and a vision simulator packaged into personalized reports, mEYE™ Guide is designed to simplify the conversation between ECPs and parents of children with myopia. With a deeper understanding of myopia, families may be more likely to choose treatment and commit long-term. At the same time, the tool aims to reduce chair time for eye care professionals, allowing them to see and treat more children.

An additional Ocumetra tool, mEYE™ Gauge, is also available to ECPs. While ocular biometry remains the gold standard for tracking myopia progression, axial length estimator mEYE™ Gauge empowers ECPs to begin integrating axial length into their myopia management routine without the significant expense of a biometry device.

“We are excited about partnering with CooperVision to help bring mEYE™ Guide and mEYE™ Gauge to a broader global audience,” said Prof. Ian Flitcroft, D.Phil, FRCOphth, Ocumetra Co-Founder and Chief Innovation Officer. “At Ocumetra we create tools that help to accelerate the adoption of evidence-based treatments to benefit children with myopia everywhere.” 

Through CooperVision’s sponsorship, mEYE™ Guide and mEYE™ Gauge will expand to support additional languages including: Traditional Chinese, Simplified Chinese, Czech, French, German, Hebrew, Hungarian, Italian, Korean, Polish, Portuguese, Russian, and Spanish. Ocumetra has plans underway for other languages as well. With these additional languages, the tools will be able to serve regions with the highest prevalence of myopia around the world.

Ocumetra’s mEYE™ Guide and mEYE™ Gauge are available on a subscription basis. A free trial (and its terms and conditions) is available at cvi.ocumetra.com.

# # #

*U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternative multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.

†Compared to a single vision 1-day lens over a 3-year period.

1. Sulley, et al. Global survey on eye care practitioner perceptions and attitudes regarding myopia and its management. Contact Lens and Anterior Eye. 2021 Feb;44(1):13.

2. Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567.

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of roughly 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Hannah Barry, Counselor, McDougall Communications
hannah@mcdougallpr.com or +1-585-645-8985